Atomoxetine functions as a selective norepinephrine reuptake inhibitor (SNRI) [1]. It selectively blocks the presynaptic transporter for norepinephrine, increasing the concentration of norepinephrine in the synaptic cleft [2]. This action is believed to be the primary mechanism by which atomoxetine exerts its therapeutic effects, particularly in the management of Attention-Deficit/Hyperactivity Disorder (ADHD) [1][3].
How does atomoxetine work in the brain?
Atomoxetine targets the norepinephrine transporter (NET) in the brain [1][2]. By inhibiting this transporter, it prevents the reabsorption of norepinephrine back into the presynaptic neuron [2]. This leads to a sustained increase in the availability of norepinephrine in the synapses, especially in brain regions like the prefrontal cortex, which are involved in attention, impulse control, and executive functions [3][4]. Unlike stimulant medications used for ADHD, atomoxetine does not significantly affect dopamine levels [5].
Is atomoxetine a stimulant?
No, atomoxetine is not a stimulant [5]. It is classified as a non-stimulant medication [1]. Stimulants, such as methylphenidate and amphetamines, primarily work by increasing both norepinephrine and dopamine levels in the brain. Atomoxetine's mechanism of action is limited to selectively inhibiting norepinephrine reuptake [5].
What is atomoxetine approved to treat?
Atomoxetine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents, and adults [3]. It is indicated for the management of symptoms associated with ADHD, including inattention and hyperactivity/impulsivity [1].
What are the potential side effects of atomoxetine?
Common side effects associated with atomoxetine can include gastrointestinal issues such as nausea, vomiting, and abdominal pain, as well as decreased appetite and weight loss [1]. Other reported side effects include fatigue, dizziness, sleep disturbances (insomnia or somnolence), and dry mouth [1][6]. In some individuals, it may also cause increased blood pressure or heart rate [1]. Rare but serious side effects can include liver problems and suicidal thoughts or behaviors, particularly in children and adolescents [1][6].
When was atomoxetine first approved?
Atomoxetine was first approved by the U.S. Food and Drug Administration (FDA) in November 2002 [3]. It is marketed under the brand name Strattera by Eli Lilly and Company [3].
How does atomoxetine's patent status affect its availability?
The patent status of atomoxetine influences the availability of generic versions [7]. While original patents provide market exclusivity for the brand-name drug, their expiration allows other pharmaceutical companies to seek approval for and manufacture generic alternatives [8]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which is crucial for understanding when generic competition might emerge [7]. The expiration of key patents for atomoxetine has paved the way for the introduction of generic formulations, generally leading to lower prices for consumers [8].
What are other non-stimulant ADHD medications?
Other non-stimulant medications approved for ADHD include alpha-2 adrenergic receptor agonists like guanfacine and clonidine [9]. These medications work differently than atomoxetine by affecting norepinephrine signaling through alpha-2 receptors in the brain, which can help improve attention and reduce impulsivity and hyperactivity [9].